SecBot SecBot
S-3/A ·Filed Jun 5, 2026

FBRX

Forte Biosciences, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001193125-26-260329
Shelf registration amendment
Actionable Insight ▼ Bearish

The shelf registration signals a high likelihood of near-term equity issuance to fund ongoing clinical trials. With only ~2.6 quarters of cash at current burn, a follow-on offering is probable within months. Traders should watch for a prospectus supplement detailing actual terms and size of any takedown.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$15.67
T+0 close · Jun 5, 2026 · via day close
Latest settled
+30.25%
T+20 · $20.41
Vs SPY
+28.62%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 8 $15.67entry
  2. T+1 · 5mo ago +8.49%α +8.78% · $17.00
  3. T+5 · 5mo ago +15.19%α +13.08% · $18.05
  4. T+20 · 4mo ago +30.25%α +28.62% · $20.41
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities (common, preferred, debt, warrants, etc.). The company is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026. The shelf enables future capital raises, likely to fund Phase 2 celiac and other trials.

Key Financial Metrics

Offering Size
$500.0M

Key Facts

  • Shelf registration of up to $500,000,000 in securities (common, preferred, debt, warrants, units)
  • Pre-revenue clinical-stage biopharma with net loss of $22.1M in Q1 2026 vs $15.7M in Q1 2025
  • Cash and cash equivalents of $58.2M as of March 31, 2026, down from $77.0M at Dec 31, 2025
  • Operating cash burn of ~$22.4M/quarter; at current burn rate, cash runway extends ~2.6 quarters
  • Lead candidate FB102 in Phase 2 celiac study (topline expected 2026), Phase 1b vitiligo and alopecia areata
  • Market cap of $338M; shelf size of $500M is ~148% of current market cap, representing massive potential dilution

Financial Impact

Shelf registration of up to $500M, representing ~148% of current $338M market cap. Q1 2026 net loss of $22.1M, cash burn of ~$22.4M/quarter.

dilutioncash runwayshare count

Risk Factors

  • Massive potential dilution: shelf size ($500M) is 148% of current market cap ($338M)
  • Cash runway of only ~2.6 quarters at current burn rate ($22.4M/quarter)
  • Pre-revenue clinical-stage company with no approved products and uncertain pipeline timelines

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
S-3/A Filing (Primary)0001193125-26-260329
Document: d117004dex231.htm0001193125-26-260329
Document: 0001193125-26-260329-index-headers.html0001193125-26-260329
Document: 0001193125-26-260329-index.html0001193125-26-260329
Document: 0001193125-26-260329.txt0001193125-26-260329

Track record

15 reports on FBRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Viewing Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026